StockData
Relay Therapeutics, Inc. logo

Relay Therapeutics, Inc. (RLAY) company profile

RLAYNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/30
$16.47−0.80 (-4.63%)

Close on Nov 17, 2026Market cap $3.61BP/E –Yield –

About Relay Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

Relay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule drug candidates. The firm concentrates its efforts on precision oncology and genetically defined diseases through targeted therapies designed to address validated biological mechanisms. Rather than offering commercialized medical products, its clinical pipeline includes experimental drug programs and therapeutic opportunities being investigated for targeted patient groups.

The company operates primarily within the United States, managing its research and laboratory activities in Massachusetts. It maintains corporate headquarters, principal executive offices, and administrative facilities located in Cambridge, Massachusetts. Relay Therapeutics carries out its operations and ongoing clinical studies across selected domestic research sites, relying on agreements with external partners, clinical investigators, and institutions to advance its investigative development programs.

Summary of the business section of Relay Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Relay Therapeutics, Inc.
Founded
2016
Headquarters
Cambridge, MA
Address
60 Hampshire Street 02139
Phone
(617) 370-8837
Employees
192, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Boston, Massachusetts

Stock & identifiers

Ticker
RLAY
Exchange
Nasdaq
IPO date
Jul 16, 2020
Shares outstanding
219M, Jul 31, 2026
Public float
$585.50M, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1812364
CUSIP
75943R102
ISIN
US75943R1023
FIGI
BBG00DSS08K9
Share class FIGI
BBG00DSS08L8
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Sanjiv PatelPresident and CEO, Director1,358,204
Donald A. BergstromPresident, R&D396,878
Thomas CatinazzoChief Financial Officer103,665
Peter RahmerSee remarks222,904
Brian AdamsChief Legal Officer371,472
Alexis BorisyDirector234,175
Mark MurckoDirector996,952
Claire MazumdarDirector–
Habib J. DableDirector–
Linda A. HillDirector–
Lonnel CoatsDirector–
Douglas S. IngramDirector25,000
Sekar KathiresanDirector–
Jami RubinDirector67,242

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$4.65M$9.12M$1.60M$20$120
FY2024$13.08M-$1.28M$5.09M$10$91
FY2023$19.77M$5.29M$6.27M$26$92
FY2022$8.12M-$5.23M$2.78M$36$89
FY2021$8.53M-$3.35M$2.26M$74$99
FY2020$3.58M$62.93M$952.65K$119$107

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Sanjiv K. Patel, M.D.
President and Chief Executive Officer
$707.85K$3.51M$424.71K–$4.65M-64%
Thomas Catinazzo
Chief Financial Officer
$486.10K$874.50K$194.44K$13.57K$1.57M-64%
Donald Bergstrom, M.D., Ph.D.
President, Research & Development
$554.25K$1.27M$249.41K$14.00K$2.09M-68%
Peter Rahmer
Chief Corporate Development Officer
$469.05K$874.50K$187.62K$14.00K$1.55M-69%
Brian Adams
Former Chief Legal Officer
$291.18K$874.50K–$11.65K$1.18M-73%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 16, 2020
Offer price
$20.00
Securities offered
20,000,000
Gross proceeds
$400.00M
Exchange
Nasdaq
First trading day
Jul 16, 2020
First-day close
$35.05+75.3%
Lock-up ends (est.)
Jan 12, 2021

“The initial public offering price of our common stock is $20.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 192 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?